Absolute, not relative, changes are important when interpreting trial data  by Kalra, Paul R. & Sharma, Rakesh
Possible implication in the inhibition of advanced glycation end product
formation. Biochem Pharmacol 1999;58:1765–73.
3. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS.
Metformin reduces systemic methylglyoxal levels in type 2 diabetes.
Diabetes 1999;48:198–202.
4. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complica-
tions: a new perspective on an old paradigm. Diabetes 1999;48:1–9.
5. Giugliano D, Ceriello A, Paolisso G, Cohen RA. Diabetes mellitus,
hypertension, and cardiovascular disease: which role for oxidative stress?
Prog Cardiovasc Dis 1995;44:363–8.
6. Galle J, Schneider R, Winner B, et al. Glycoxidized LDL impair
endothelial function more potently than oxidized LDL: role of en-
hanced oxidative stress. Atherosclerosis 1998;138:65–77.
7. Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative
stress in the pathogenesis of endothelial dysfunction in non-insulin-
dependent diabetes mellitus: an hypothesis. Atherosclerosis 1998;141:
17–30.
Absolute, Not Relative, Changes Are
Important When Interpreting Trial Data
Tsutamoto et al. (1) have recently reported on the beneficial effects
of spironolactone on plasma neurohormones and echocardio-
graphically derived left ventricular (LV) volume and mass indices
in patients with nonischemic congestive heart failure. Though
spironolactone is known to reduce morbidity and mortality in
severe heart failure, many of the mechanisms underlying these
effects have yet to be fully elucidated (2). Because aldosterone has
direct myocardial actions that may play an important role in LV
remodeling, it is particularly relevant to investigate the effects of
spironolactone on this process.
However, several points need careful consideration when inter-
preting the data presented by Tsutamoto et al. (1). First, the
investigators state that no significant differences existed between
the placebo- and spironolactone-treated groups at baseline. How-
ever, this seems somewhat surprising considering that the mean
baseline plasma-active renin concentration was 234 pg/ml in the
placebo group but only 93 pg/ml in the spironolactone group.
Furthermore, it appears that LV ejection fraction (LVEF) was
greater and both LV end diastolic volume and mass were lower in
the placebo group. Although these differences in echocardio-
graphic parameters did not reach significance, they have an
important bearing when interpreting the results after four months
of active therapy. The researchers concluded that spironolactone
treatment resulted in an improvement in indices of LV remodel-
ing, which was based upon a significant difference in changes of
echocardiographic parameters between the two groups at four
months. However, when determining the clinical relevance of a
novel therapy in any placebo-controlled study it is imperative to
compare the absolute means between the two groups at follow-up.
In our opinion, the investigators should have performed an
unpaired t test between the groups after four months of treatment.
As this has not been mentioned in the report by Tsutamoto et al.
(1), should we assume that these differences did not reach
statistical significance? This possibility is supported by the absolute
values given in the researchers Table 2 (1). For example, although
spironolactone therapy resulted in an increase in LVEF of 2.8%
(p  0.05), the absolute value of 35% after four months of
treatment was similar to that in the placebo group (baseline,
36.6%; four months, 36.3%). This demonstrates the potential
pitfalls of preenting relative changes as opposed to absolute values
in assessing the clinical benefits of a therapeutic agent.
One of the reasons that Tsutamoto et al. (1) were unable to
demonstrate a significant improvement in indices of LV remod-
eling (in terms of absolute values) may relate to the fact that the
measurements were made using echocardiography. This technique
is known to have poor reproducibility when applied to subjects
with impaired LV function. In contrast, cardiac magnetic reso-
nance imaging provides highly reproducible assessments of cardiac
volumes, function and mass in patients with heart failure (3). It is
especially important to use a technique with high reproducibility
when attempting to demonstrate significant differences using
relatively small numbers of participants, as was the case in the
study by Tsutamoto et al. (1).
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REPLY
We appreciate the important remarks by Kalra et al. on our article
(1). We compared left ventricular (LV) volume and mass, as well
as plasma levels of atrial natriuretic peptide (ANP), brain natri-
uretic peptide (BNP) and procollagen type III aminoterminal
peptide (PIIINP), before and after treatment with spironolactone
or placebo. The LV volume and mass were significantly decreased
in the spironolactone group, but not in the placebo group. Plasma
levels of ANP, BNP and PIIINP were significantly decreased by
spironolactone, but did not change in the placebo group. A
significant positive correlation existed between the changes of
PIIINP and changes of the LV mass index with spironolactone
treatment. These findings indicate that four months of spirono-
lactone treatment improved LV volume and mass and decreased
the plasma level of BNP in nonischemic patients with congestive
heart failure (CHF).
In our study (1), to the evaluation of LV mass and LV function
in nonischemic CHF patients, we performed M-mode echocardi-
ography with two-dimensional (2-D) monitoring using a Sono-
layer phased-array sector scanner in a blinded fashion before and
after four months of treatment with spironolactone or placebo.
The LV volumes were calculated using Teichholtz’s formula, and
the LV ejection fraction was determined. The LV mass was
calculated using a method reported previously (2). An earlier study
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